AT
ABLi Therapeutics, Inc.
SEC filingPharmaceuticals · Atlanta, GA
Amount raised$1Msold at filing
Total offering$1M
Investors in the raise10count reported to the SEC
FiledJan 13, 2026first sale Sep 15, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Jeffrey H. YoungDirector
Milton H. WernerExecutive Officer, Director
Garth H. Lees-RolfeExecutive Officer
Anastasia H. DaifotisDirector
Executive officers, directors and promoters as listed on the Form D.